The following criteria is provided for health care professionals.

Inclusion Criteria:

• ≥18 years of age at the time of informed consent form (ICF) signature
• Adult patients after failure of three or more lines of therapy including an IMiD (e.g., lenalidomide or pomalidomide), a proteasome inhibitor (e.g., bortezomib, carfilzomib), and an approved anti-CD38 antibody (e.g., daratumumab, isatuximab), and have documented evidence of disease progression (IMWG criteria)
• Must have received ≥2 consecutive cycles of treatment for at least three prior regimens unless deemed refractory tot hat regimen (i.e., progressive disease as the best response)
• Must be refractory to the last treatment regimen (defined as progressive disease on or within 60 days measured from last dose of last regimen).
• Measurable disease at enrollment as defined by the protocol
• Eastern Cooperative Oncology Group (ECOG) performance status that is either 0 or 1 at screening
• Must have a leukapheresis material of non-mobilized cells accepted for manufacturing

Exclusion Criteria:

• Prior administration of a genetically modified cellular product including prior BCMA CAR-T therapy.
• Participants who have received prior BCMA -directed bi-specific antibodies or anti-BCMA antibody drug conjugate.
• Prior autologous SCT within 3 month or allogenic SCT within 6 months prior to signing informed consent.
• Plasma cell (PC) leukemia and other plasmacytoid disorders, other than MM
• POEMS syndrome
• Active central nervous system (CNS) involvement by malignancy
• Patients with active neurological auto immune or inflammatory disorders
• Inadequate cardiac, renal, hepatic or hematologic function as defined in the protocol.

Other protocol-defined Inclusion/Exclusion may apply.